AAN 2021 | Pregnancy outcomes following direct brain-responsive neurostimulation in women with epilepsy
Kimford Meador, MD, FAAN, Stanford University, Stanford, CA, outlines the findings of the first report of pregnancy outcomes in pregnant women with epilepsy treated with direct brain-responsive neurostimulation to date. 14 pregnancies in 10 women were included in the study which analyzed obstetric complications and fetal outcomes. No stimulation-exposed pregnancies had major congenital malformations and the pregnancy complications observed were within the expected range for women with epilepsy. A greater sample size is needed for the validation of these results. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.
Disclosures
Grants: NIH/NINDS 2U01-NS038455-11A1. Meador (Multi-PI). “Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs.”*
NIH/NINDS R01NS088748-01. Drane (PI). “Dissecting the Cognitive Roles of Hippocampus & Other Temporal Lobe Structures.” Role: Co-I.
Medtronics. Halpern (PI). “Stereotactic Laser Ablation for Temporal Lobe Epilepsy (SLATE).” Role: Co-I.
Eisai Inc. Razavi (PI). “Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures.” Role: Co-I.
Sunovion Pharma. Meador (PI). “Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults.”
Consultant (no personal income): Epilepsy Consortium (funds paid to my university)* for Eisai, GW Pharmaceuticals, Medtronics, NeuroPace, Novartis, Supernus, Upsher Smith Labs, UCB Pharma, and Vivus Pharm.
Other: Clinical income: EEG procedures and patient care*
*Items with asterisk involve income > $10,000 for recent years.
